When his insurer denied a newly approved lung cancer therapy, @StanfordCAREs' Bryant Lin, MD, posted about it on LinkedIn. It was approved within hours. “What happens to everyone else?” Watch his Medicine Grand Rounds talk: https://t.co/mDWdL6Sa83
Another contradictory result, Li et al in @AnnSurgOncol show that pre-operative myasthenia is associated with worse outcomes at 5-years in thymoma patients, 8.6-point difference in OS and 7.6 points for recurrence favoring patients who did not have MG.
https://t.co/qObXGH6iD6
FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class?
https://t.co/niZ501PNO5
November is #LungCancerAwarenessMonth!
A multimodal AI model can now predict immunotherapy outcomes for advanced NSCLC better than standard biomarkers. This landmark international study of 2,396 patients offers major new hope for lung cancer. #AIinCancer
https://t.co/TNZ8XobCwr
Great work by @eripietroluongo and @FabioSalomone22 we presented at #ITMIG26
Only 7% of thymic epithelial tumour trials assessed PROs, despite 96% of daily-life-limiting symptoms lacking objective correlates.
Time to put patients’ voices at the heart of toxicity assessment
#LALCA26 #PatientReportedOutcomes #QoL
Can MTAP deletion become an actionable Achilles’ heel in cancer?
Pleased to share our review in The Oncologist on the MTAP–PRMT5 synthetic lethal axis: MTA-cooperative inhibitors, early clinical signals, biomarkers and resistance. @gbanna74@OncJournal
🔗 https://t.co/h19z6sA3EN
kudos to the co-authors for their effort @Maxime_Borgeaud@mihaela_aldea dr Koessler and Dr Genoud @hug_ge@DOncologie
Every three minutes, someone is diagnosed with #lungcancer. But today, the outlook is better than ever, thanks in part to clinical trials that provide patients with the newest targeted treatments, including immunotherapy. 🫁 #LungCancerAwareness#lcsm https://t.co/KciXfExBpx
We are hiring! @PennCancer@Penn@PennMedicine is seeking Assistant Professors in Thoracic Oncology (Academic Clinician Track).
Join our team to deliver outstanding patient care, educate the next generation of oncologists, and advance excellence in lung cancer care.
https://t.co/oxRqhWRRMO
Are we seeing the ramp-up for thymic tumors similar to what happened for lung cancer? We owe our patients more innovative tools, therapeutic avenues, and closer collaborations, and #ITMIG26 is all about that.
📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca.
📊 mINV-PFS: 22 mo | OS: 40 mo
🚀 Can IO, ADCs & bispecifics move to 1st line?
💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies!
🔗 https://t.co/Hs9txLiDuG
In thymoma, autoimmunity affects 40% of pts and may share one mechanism @NEJM: AIRE loss → increase IFNγ–JAK–STAT pathway mimicking APS-1, with decrease in IFNγ and CXCL9 upon Ruxolitinib. Antitumor activity was not evaluated, so caution is needed.
https://t.co/QMXV05Qntk
The latest version of the ASCO Multiple Myeloma Living Guideline is out!
All published phase 3 data is reviewed every 8 weeks and recommendations are updated in real-time.
We are continuing to refine algorithms for relapsed/refractory myeloma as time goes on.
https://t.co/0gEvNrYM3G
ASH welcomes its newly elected Executive Committee members! 👏
Bringing extensive experience and a shared commitment to advancing hematology, these leaders will help guide the Society's work in the years ahead.
Read the full announcement: https://t.co/6Bwo6GjdAg
Our own @marinagarassino@UCCancerCenter@UChicagoMed chair of the Thymic Tumors state of the art and addition of Ivonescimab in TC 1L and Rivoceranib Thymoma/TC further lines